Aadi Bioscience Inc reports results for the quarter ended in March - Earnings Summary

Whitehawk Therapeutics

12/05/2022 14:31

* Aadi Bioscience Inc  AADI.OQ  reported a quarterly
adjusted loss
of 66 cents​​ per share for the quarter ended in March. The mean
expectation of five analysts for the quarter was for a loss
of 71 cents per share.
    * Revenue was $2.31 million​;  analysts expected $501.00
thousand. 
    * Aadi Bioscience Inc's reported EPS for the quarter was a
loss
of 66 cents​.
    * The mean earnings estimate of analysts had risen by
about 16.6%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Aadi Bioscience Inc shares had fallen by 31.8% this
quarter and
lost 52.1% so far this year.
    * The company reported a quarterly loss of $13.86 million.
    * Wall Street's median 12-month price target for Aadi
Bioscience
Inc is $49.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated May 12 at 01:31 p.m.  ​All
figures in US dollars unless otherwise stated